1. Single Cell Analysis Systems for Therapeutic Discovery
Name, Date and Conference/Client Title
3rd February 2016.

2. COMPANY INTRODUCTION
Sphere Fluidics (SF) is an established Life Sciences Tools spin-out from
the University of Cambridge focussing on Single Cell Analysis.
Originally commercialised Research Instruments and
Consumables (c. 40 products) and R&D Collaborations
to generate rapid income and learn the market.
Strategy has evolved to now developing Industrial Systems that
enable rapid ultra-high-throughput discovery of therapeutics
from single cells (e.g. Cyto-Mine®).
IP Protection: 54 patents and 2 Trademarks created with over
£12M of grants and funding.
Raised £4M in funding to date, income-generating and now
raising ~£6M (£4.6M already committed; Pre-money of £10M).

3. Core Technology: Encapsulation and
Assay of Single Cells in Picodroplets
Name, Date and Conference/Client Title

4. PICODROPLETS – MINIATURE “TEST TUBES” FOR SINGLE CELLS
Novel microfluidics can produce,
manipulate, analyse, sort, fuse, split,
retrieve and dispense millions of
picodroplets per biochip per day.
Picodroplets are small
volume (pl-nl) aqueous
droplets in oil made
at rates of > 100,000
per min. They enable
testing of trapped, secreted
molecules (e.g. antibodies).
Picodroplets are stabilised using
novel biocompatible surfactants and
are useful for many weeks.
A microfluidic
biochip (a few cms in size)
Oil
Cells
Picodroplets containing
single cells
Stored
picodroplets

5. Cell growth (e.g. T-cells)
EXAMPLE PICODROPLET OPERATIONS
Cell encapsulation
Sorting
Spacing
Picodroplet splitting
Cell growth (e.g. T-cells)
Fusion
Cell division occurs within 48 hours

6. SF TECHNOLOGY: FEATURES AND BENEFITS
High-throughput: can perform millions of single cell tests per biochip
and isolate rare variants from a vast population.
Miniaturised: can save up to £0.5M per R&D program (e.g. GSK).
Enabling: Screen entire libraries significantly improving rates of finding
unique variants or high expressors.
Picodroplet fusion: enables inline co-incubation and novel functional
assays – impossible to do by conventional techniques.
Picodroplet splitting: facilitates mass spectrometry and other analyses
allowing retrieval of “hit” replicates - gives > 20-fold faster analysis.

7. Target markets
Name, Date and Conference/Client Title

8. PRIORITISED MARKETS (ADDRESSABLE) - A £BILLION
1) Biopharmaceutical Discovery & Development
(£214 MM growing at 10% p.a.).
2) Synthetic Biology - Bioprocessing
(£135 MM growing at 42% p.a.).
3) Stem Cell Engineering, Isolation and Analysis
(£580 MM growing at 14% p.a.).
4) Single Cell Disease Research
(Infectious Diseases: £60 MM growing at 6% p.a.).
5) Single Cell Diagnostics and Prognostics
- Cancer Market (Total): £20 billion growing at 15% p.a.

9. Cyto-Mine®: Next Generation
Platform for Biopharmaceutical
Discovery and Development
Name, Date and Conference/Client Title

10. CYTO-MINE® (THE INDUSTRIAL SYSTEM) OVERVIEW
The Single Cell Analysis & Monoclonality Assurance System:
Single cell analysis, cloning and isolation techniques are critical for biopharmaceutical discovery and development.
Conventional techniques offer partial solutions performing some of the following: high-throughput screening, protein secretion assays, rapid cell sorting, single cell dispensing to microplates and monoclonality verification.
Cyto-Mine® will be the world’s first integrated device specifically designed to automatically perform all of these functions in a single system.

11. COMPETITIVE ADVANTAGE OF CYTO-MINE®

12. PROJECTED SALES: CYTO-MINE® PRIMARY MARKET
Cyto-Mine®: An integrated, high-throughput
single cell analysis platform using optical detection.
Primary Market: Biopharmaceuticals
Addressable User Base: 480 international Biopharma firms, CROs and Core Labs
Addressable Market: £214 MM.

13. PROJECTED SALES: CYTO-MINE® IN ALL 5 MARKETS

14. Financial Projections
Name, Date and Conference/Client Title

15. FINANCIAL PROJECTIONS
Cyto-Mine® Units Sold:
Other Instruments Sold:

16. USE OF FUNDS
 Raising circa. £6 M of investment (Pre-money: £10 M; £4.6 M already
committed), ~£1.4M investment opportunity to:
Commercialise the world‘s first integrated, single cell analysis
system (Cyto-Mine®) in Biopharmaceutical Discovery and Devt.
Position Cyto-Mine® technology into other new markets.
Progress development and sales of the ESI-Mine™ system.
Enable expansion of facility, the commercial and technical teams.
Exit is by Trade Sale within the next years to a global, Life Sciences
company for £100M - £200M.
Full business plan and due diligence materials available.

17. THANK YOU Investor Meetings: Ongoing. Key Contact: Dr. Frank F. Craig
CEO, Sphere Fluidics Ltd
Tel: /